GreyRigge Associates partners with NG Bio to accelerate VC investment
Posted on 18 Feb 2025
London, United Kingdom – [18/02/25] – NG Bio, an early-stage venture investor and venture builder, and GreyRigge Associates, a leading international biotech consultancy company, today announced a strategic partnership to accelerate the development and commercialisation of groundbreaking biopharmaceutical innovations.
This collaboration brings together NG Bio's proven ability to identify, build, invest in and nurture early stage biotech companies with therapies in autoimmune and inflammatory disease with GreyRigge's extensive expertise in providing support to early-stage biotech companies. This partnership will enable the two companies to provide biotech startups and spinouts with both funding and experience to successfully allow rapid progress from a discovery company to a clinical-stage company.
"It’s fantastic to have GreyRigge alongside us" said Tim Carlton, Director of Drug Development at NG Bio. "In particular, their expertise in CMC as well as regulatory strategy is invaluable to our portfolio companies as they advance their groundbreaking therapies into the clinic. Together, we will bridge the gap between research and real-world impact, accelerating the work of these entrepreneurs to create transformative treatments.
Dr. Lee Smith, Principal Consultant at GreyRigge, added, "We are really excited to work with NG Bio and their portfolio companies. This partnership aligns perfectly with our mission to support the development of innovative medical products to improve patient lives. By leveraging our extensive biopharmaceutical industry experience combined with NG Bio’s investment and venture creation expertise, this will allow early-stage companies to overcome key challenges that transform innovative ideas into life-changing therapies”.
About NG Bio
NG Bio, an early-stage investor and venture builder addressing the harmful immune responses, such as inflammation, that cause or exacerbate many of the major human diseases. By tackling these, we extend human health span and longevity.
About GreyRigge Associates Limited
GreyRigge Associates is a global biotech partner delivering consultancy, management expertise and training across the entire product development journey. GreyRigge’s extensive biopharmaceutical industry experience and pragmatic, agile approach enables transformational success by accelerating client medicines to market. Partnering with NG Bio, we perform technical due diligence and support that de-risks and accelerates the return on investment.
Contact details:
NG Bio: www.ngbio.co.uk | info@ngbio.co.uk
Greyrigge Associates: www.greyrigge.com | 0118 979 1169 | contactus@greyrigge.com
View more blog posts
01
Live Attenuated Viral Vaccines Advancements
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.
02
Hope for Chlamydia STI Vaccine After Promising Initial Results
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.
03
Gene Therapy for Rare Disorders
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.
04
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
CEPI awards US$21 million to Themis Bioscience.
05
GreyRigge Associates partners with NG Bio to accelerate VC investment
NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation
06
Greyrigge Associates partner with SciPot Consultancy
GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy
07
Building Biotech: Being ready for AI
AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.
08
Building Biotech: How COVID-19 changed development forever
The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.
09
Building Biotech: Animal Models and Beyond - What's Next?
Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.